Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × DT2216 × 90 days × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1

Interventions

pembrolizumab 113 Specimen Handling 113 Cyclophosphamide 97 Magnetic Resonance Spectroscopy 90 Biopsy 84 fludarabine 73 Nivolumab 54 venetoclax 48 Carboplatin 35 Cetuximab 34 Radiotherapy 33 fludarabine phosphate 32 Paclitaxel 32 Gemcitabine 32 Cisplatin 32 Bevacizumab 31 Fluorouracil 29 atezolizumab 28 Azacitidine 28 Ipilimumab 25 Injections 24 Dexamethasone 24 Cytarabine 24 durvalumab 23 Radiosurgery 23 Lenalidomide 23 Temozolomide 22 Oxaliplatin 22 Leucovorin 21 Irinotecan 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06964009 2026-01-08

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Dana-Farber Cancer Institute

Phase 1 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡